Table 2

Multivariate analyses

VariablesNRMRelapseDFSOS
HR95% CIPHR95% CIPHR95% CIPHR95% CIP
Entire cohort             
 Age at alloBMT 1.04 1.01-1.07 .016    1.02 1.00-1.04 .0292 1.02 1.00-1.04 .0167 
 HCT-CI 1-2 vs 0          1.39 0.75-2.6 .2975 
 HCT-CI ≥3 vs 0          2.1 1.17-3.77 .0127 
 Bu/Flu vs Bu/Cy       0.61 0.35-1.08 .091    
 Active disease vs morphologic CR    2.31 1.46-3.64 .0003 1.55 1.05-2.29 .0279    
 Patient CMV serology positive vs negative 2.74 1.33-5.66 .0063    1.66 1.15-2.40 .0073 1.44 0.96-2.16 .081 
 Donor CMV serology positive vs negative    1.63 1.05-2.53 .03       
 TNC dose    0.79 0.67-0.93 .005 0.82 0.71-0.95 .0066 0.79 0.68-0.92 .0018 
AML patients             
 Age at alloBMT 1.04 1-1.07 .032    1.01 0.99-1.03 .2568 1.01 0.99-1.04 .2352 
 HCT-CI 1-2 vs 0       1.52 0.71-3.25 .2831 1.51 0.69-3.32 .303 
 HCT-CI ≥3 vs 0       1.9 0.96-3.78 .0662 1.82 0.89-3.71 .0986 
 Bu/Flu vs Bu/Cy       0.48 0.21-1.11 .0858 0.39 0.14-1.08 .0699 
 Active disease vs morphologic CR    2.51 1.35-4.66 .0036 2.26 1.39-3.67 .001 1.87 1.12-3.12 .0159 
 Patient CMV serology positive vs negative 4.13 1.58-10.8 .0038    1.91 1.16-3.13 .0105 1.61 0.96-2.71 .0696 
 TNC dose    0.75 0.59-0.95 .018 0.77 0.64-0.94 .0095 0.74 0.6-0.91 .0035 
 Cytogenetics* adverse vs favorable/intermediate    2.7 1.46-4.98 .0015 2.2 1.31-3.7 .0028 2.16 1.27-3.68 .0044 
VariablesNRMRelapseDFSOS
HR95% CIPHR95% CIPHR95% CIPHR95% CIP
Entire cohort             
 Age at alloBMT 1.04 1.01-1.07 .016    1.02 1.00-1.04 .0292 1.02 1.00-1.04 .0167 
 HCT-CI 1-2 vs 0          1.39 0.75-2.6 .2975 
 HCT-CI ≥3 vs 0          2.1 1.17-3.77 .0127 
 Bu/Flu vs Bu/Cy       0.61 0.35-1.08 .091    
 Active disease vs morphologic CR    2.31 1.46-3.64 .0003 1.55 1.05-2.29 .0279    
 Patient CMV serology positive vs negative 2.74 1.33-5.66 .0063    1.66 1.15-2.40 .0073 1.44 0.96-2.16 .081 
 Donor CMV serology positive vs negative    1.63 1.05-2.53 .03       
 TNC dose    0.79 0.67-0.93 .005 0.82 0.71-0.95 .0066 0.79 0.68-0.92 .0018 
AML patients             
 Age at alloBMT 1.04 1-1.07 .032    1.01 0.99-1.03 .2568 1.01 0.99-1.04 .2352 
 HCT-CI 1-2 vs 0       1.52 0.71-3.25 .2831 1.51 0.69-3.32 .303 
 HCT-CI ≥3 vs 0       1.9 0.96-3.78 .0662 1.82 0.89-3.71 .0986 
 Bu/Flu vs Bu/Cy       0.48 0.21-1.11 .0858 0.39 0.14-1.08 .0699 
 Active disease vs morphologic CR    2.51 1.35-4.66 .0036 2.26 1.39-3.67 .001 1.87 1.12-3.12 .0159 
 Patient CMV serology positive vs negative 4.13 1.58-10.8 .0038    1.91 1.16-3.13 .0105 1.61 0.96-2.71 .0696 
 TNC dose    0.75 0.59-0.95 .018 0.77 0.64-0.94 .0095 0.74 0.6-0.91 .0035 
 Cytogenetics* adverse vs favorable/intermediate    2.7 1.46-4.98 .0015 2.2 1.31-3.7 .0028 2.16 1.27-3.68 .0044 
*

By refined MRC criteria as per Grimwade et al.29 

View Large